Vaccines recombinant subunit

A number of such recombinant (subunit) vaccines have now been approved for general medical use (Table 13.9). The first such product was that of hepatitis B surface antigen (rHBsAg), which gained marketing approval from the FDA in 1986. Two billion people are infected with hepatitis B worldwide, 350 million individuals suffer from life-long chronic infection, and more... 

Table 13.9 Recombinant subunit vaccines approved for human use...

It seems likely that many such (recombinant) subunit vaccines will gain future regulatory approval. One such example is that of Bordetella pertussis subunit vaccine. B. pertussis is a Gramnegative coccobacillus. It is transmitted by droplet infection and is the causative agent of the upper respiratory tract infection commonly termed whooping cough . 

Most of the recombinant subunit vaccines tested in the first half of this decade employed gp 120 or gp 160 expressed in yeast, insect or mammalian (mainly CHO) cell lines. Eukaryotic systems facilitate glycosylation of the protein products. Like all subunit vaccines, these stimulate a humoral-based immune response but fail to elicit a strong T-cell response. The failure to elicit a cell-based... 

Recombinant subunit vaccine, in which a pathogen s DNA is inserted into a cell or organism, which then produces massive quantities of the pathogen that are used in place of the whole pathogen. 

Dagouassat, N., Haeuw, J.F., Robillard, V., Damien, F., Libon, C., Corvaia, N., Lawny, F., Nguyen, T.N., Bomiefoy, J.Y. and Beck, A., 2001a, Development of a quantitative assay for residual host cell proteins in a recombinant subunit vaccine against human respiratory syncytial virus. J. Immunol. Methods 251 151-159. 

SUN, Y., LIU, C.-S. and sun, l. (2010a) Identification of an Edwardsiella tarda snrface antigen and analysis of its immnnoprotective potential as a pnrified recombinant subunit vaccine and a snrface-anchored snbnnit vaccine expressed by a fish commensal strain. Vaccine 28, 6603-6608. 

---